Scholarlink

Background <p>Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Approximately 20–40% of patients exhibit eosinophilic inflammation; a phenotype linked to higher exacerbation risk. Mepolizumab, an anti-IL-5 biologic, has shown clinical benefit in reducing exacerbations among eosinophilic COPD patients. Its cost-effectiveness, however, remains uncertain in low- and middle-income countries.</p> Methods <p>A Markov model was developed to estimate the long-term cost-effectiveness of mepolizumab plus triple therapy versus triple therapy alone in eosinophilic COPD from the Colombian healthcare system perspective. Clinical effectiveness was informed by a meta-analysis of five randomized controlled trials. Costs and utilities were obtained from Colombian sources. A lifetime horizon, 5% discount rate, and willingness-to-pay (WTP) threshold of $5,180 USD/QALY were applied. Deterministic and probabilistic sensitivity analyses were conducted.</p> Results <p>Mepolizumab reduced exacerbation risk by 14% (RR: 0.86; 95% CI: 0.77–0.95). The incremental cost-effectiveness ratio was $45,192 per QALY gained, exceeding the WTP threshold. Net monetary benefit favored standard care, and the probability of cost-effectiveness was 0% under base-case assumptions.</p> Conclusion <p>Although clinically effective, mepolizumab is not cost-effective in Colombia at current pricing. Price reductions and outcome-based reimbursement strategies are needed to improve economic viability.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical efficacy and cost-effectiveness of mepolizumab for COPD with type 2 inflammation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月7日

查看全文
  • Jefferson Antonio Buendía,
  • Diana Guerrero Patiño,
  • Oscar Muñoz Mejia,
  • Carlos Celis Preciado

摘要

Background

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Approximately 20–40% of patients exhibit eosinophilic inflammation; a phenotype linked to higher exacerbation risk. Mepolizumab, an anti-IL-5 biologic, has shown clinical benefit in reducing exacerbations among eosinophilic COPD patients. Its cost-effectiveness, however, remains uncertain in low- and middle-income countries.

Methods

A Markov model was developed to estimate the long-term cost-effectiveness of mepolizumab plus triple therapy versus triple therapy alone in eosinophilic COPD from the Colombian healthcare system perspective. Clinical effectiveness was informed by a meta-analysis of five randomized controlled trials. Costs and utilities were obtained from Colombian sources. A lifetime horizon, 5% discount rate, and willingness-to-pay (WTP) threshold of $5,180 USD/QALY were applied. Deterministic and probabilistic sensitivity analyses were conducted.

Results

Mepolizumab reduced exacerbation risk by 14% (RR: 0.86; 95% CI: 0.77–0.95). The incremental cost-effectiveness ratio was $45,192 per QALY gained, exceeding the WTP threshold. Net monetary benefit favored standard care, and the probability of cost-effectiveness was 0% under base-case assumptions.

Conclusion

Although clinically effective, mepolizumab is not cost-effective in Colombia at current pricing. Price reductions and outcome-based reimbursement strategies are needed to improve economic viability.